Newsletter Issue #5 — How They Banned the Bear (The Three-Year War on LSD)

SET I — Cold Open: The Experts Said Don't

The most striking feature of the 1966 Senate hearings on LSD is that the government's own expert witnesses argued against the policy outcome that resulted.

NIMH Director Yolles warned against filling jails with college students.
FDA researcher Szara cautioned against letting "undue hysteria destroy a valuable tool of science."
Senator Robert F. Kennedy—whose wife Ethel had been treated with LSD therapeutically—explicitly challenged the FDA's reversal, asking how a drug considered valuable months earlier had suddenly become so despised.

The legislative outcome was driven by political imperatives that overrode the expert consensus presented in the hearings themselves.

And the man who gave abstract panic a concrete human target was a 5'7" chemist with a hairy chest and a hi-fi obsession.

SET I — Act One: The Three Stages

Criminalization wasn't a single event. It was a three-stage process spanning four years:

Stage 1 — State Bans (1966)

May 30, 1966: Nevada and California simultaneously sign prohibition bills
Nevada's takes effect immediately; California's effective date is October 6
The LA Times runs "LSD Millionaire" on October 5—the day before the ban kicks in
The Love Pageant Rally draws nearly 1,000 people and three bands (including the Grateful Dead) to Golden Gate Park on the very day of criminalization, organized in explicit opposition to "the fear addiction of the general public as symbolized in this law"

Stage 2 — Federal Possession (1968)

The Staggers-Dodd Bill (H.R. 14096) criminalizes possession federally on October 24, 1968
Not heavily enforced initially

Stage 3 — Schedule I (1970)

The Comprehensive Drug Abuse Prevention and Control Act creates the Schedule I framework
LSD placed alongside heroin—defined as having "no currently accepted medical use" and "high potential for abuse"
This classification persists today, 55 years later, despite ongoing FDA-approved clinical trials

SET I — Act Two: The Prohibition Backfire

California's October 6, 1966 ban produced measurable paradoxical effects.

The Haight-Ashbury neighborhood was transformed into what observers called "a neighborhood of outlaws" where "acid was a staple of community culture." If anything, prohibition in California only made LSD more popular.

Production simply relocated. Tim Scully established a new lab in Denver in early 1967. Owsley continued producing—196 grams in 1967, of which 96 grams were confiscated.

The structural mechanism is logically sound and historically documented: criminalization removed quality-focused producers first, because they attracted the most law enforcement attention. Owsley's December 1967 arrest removed the original quality standard-setter. His imprisonment from 1970–72 coincided with Scully's voluntary retirement from clandestine chemistry in August 1970, leaving Nick Sand as the sole carrier of the Owsley method.

The people most committed to purity and precise dosing were the easiest to find and the first to fall. What replaced them was less rigorous, less documented, and less safe.

I think about this pattern a lot. When you criminalize something, you don't eliminate it. You just kill off the people who were doing it carefully.

SET II — The Owsley-Leary Fault Line

Owsley's quote from Storming Heaven: Leary caused "inestimable damage" and "the draconian laws dating from 1966 are almost entirely of his doing."

This reflects a real dynamic:

Leary's testimony comparing LSD to cars was tone-deaf
His public persona made psychedelics politically toxic
Nixon explicitly targeted him as "the most dangerous man in America"

But the legislative record shows criminalization was already being driven by:

Governor Brown's "young thrill seekers" framing
Senator Dodd's pre-existing anti-drug agenda
FDA regulatory momentum dating to 1953
Media coverage of campus drug use

All of which preceded or ran parallel to Leary's most provocative public statements.

Stanley's critique likely also reflects personal grievance. He valued discretion and quality control. Leary's mass evangelism threatened the underground distribution network Stanley had built. The craftsman despised the evangelist—not because the evangelist was wrong about the substance, but because he was catastrophically wrong about the strategy.

DRUMS/SPACE — Owsley's Regulatory Vision (50 Years Early)

Here's the part that resonates now:

Owsley argued the government should have licensed and regulated LSD labs rather than criminalizing them.

In 2025, this position maps onto the actual emerging framework:

The DEA has escalated psilocybin production quotas from 30 grams to a proposed 40,000 grams annually
Ohio State holds a DEA license to grow psilocybin mushrooms
Texas has allocated $50M for ibogaine research funding
MAPS placed its validated MDMA synthesis in the public domain
Usona publishes its psilocybin synthesis under Creative Commons

Owsley's convergences with the modern framework:

Both center pharmaceutical-grade manufacturing quality as a prerequisite
Both envision dedicated facilities with controlled production environments
Both assume scaling is necessary and desirable

Owsley's divergences:

His model assumed manufacturing purity alone validated distribution
The modern framework requires Phase 1–3 clinical trials, IRB oversight, and post-market surveillance
The FDA's rejection of Lykos/MAPS' MDMA application—despite positive Phase 3 data—demonstrates regulatory stringency that goes far beyond quality control
The multi-agency coordination required (FDA IND, DEA registration, state licensing, IRB approval, GMP sourcing) is structurally antithetical to Owsley's individual-craftsman model

He was right about the destination. He was wrong about how simple the road would be.

ENCORE — The Open-Science Thread

The most striking ideological continuity:

1966: Owsley and Scully operate under a stated mission to "turn the whole world on," viewing psychedelic production knowledge as a public good
2020s: MAPS places its fully validated cGMP MDMA synthesis in the public domain. Usona publishes its psilocybin Investigator's Brochure under Creative Commons. Scully designates Erowid as literary executor for his manufacturing history documentation.

The belief that psychedelic synthesis knowledge should be openly accessible rather than proprietary runs as a continuous thread from Owsley's basement lab to 21st-century nonprofit research—even as for-profit entities like Compass Pathways and MindMed pursue patent-protected approaches.

Owsley's real legacy isn't the acid.

It's the principle that the recipe belongs to everyone.

Sources / Further Reading

*Jay Stevens, Storming Heaven: LSD and the American Dream*** — Owsley-Leary dynamic, legislative history
United States v. Owsley Stanley (9th Cir., 1971) — landmark case, forensic purity data
Erowid Center — Scully's Underground LSD Manufacturing History Project
MAPS Public Benefit Corporation — open-access MDMA synthesis documentation
Usona Institute — Creative Commons psilocybin synthesis
1966 Senate Subcommittee hearings — expert testimony opposing criminalization
*Robert Greenfield, Bear*** — biography with production timeline

Start listening All newsletter issues